Navigation Links
Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
Date:12/2/2008

SOUTH SAN FRANCISCO, Calif., Dec. 2 /PRNewswire/ --Cerimon Pharmaceuticals, Inc. announced today that James S. Shannon, M.D., has been appointed to the Company's Board of Directors. Dr. Shannon is a recognized pharmaceutical industry leader with more than 20 years of experience in senior development positions, most recently serving as Head of Global Development at Novartis Pharma AG in Basel, Switzerland.

"We are thrilled to welcome Dr. Shannon to our Board of Directors," stated Paul J. Sekhri, Chief Executive Officer of Cerimon Pharmaceuticals. "Dr. Shannon's expertise in identifying and advancing drug development candidates will be of great value as we seek to expand and deepen Cerimon's clinical-stage pipeline."

Dr. Shannon began his career in the pharmaceutical industry at Sterling Winthrop, where he attained the position of Senior Vice President, Clinical Development. Dr. Shannon headed Global Clinical Development during Sterling's alliance with Sanofi to develop Clopidogrel (Plavix(R)). Following this, Dr. Shannon joined Sandoz in Switzerland as Head of Drug Registration and Regulatory Affairs. He spearheaded the integration of R&D programs during Sandoz' merger with Ciba-Geigy, creating the renowned Novartis pipeline. Subsequently, Dr. Shannon held senior development positions at Novartis, ultimately being named Head of Global Development. Under Dr. Shannon's leadership, numerous drugs were developed and approved, including Diovan(R), Tekturna(R), Gleevec(R), Femara(R), Zometa(R), Reclast(R), Lucentis(R) (ex-US), Starlix(R), Visudyne(R) and Xolair(R).

Dr. Shannon received his undergraduate and postgraduate degrees from Queen's University of Belfast, where he was trained in medicine and cardiology. He also became a Member of the Royal College of Physicians (UK).

About Cerimon Pharmaceuticals

Cerimon Pharmaceuticals, Inc.,
'/>"/>

SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
2. Cerimon Pharmaceuticals to Present at the 2007 BIO Investor Forum
3. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
4. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
5. Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
6. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
7. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
8. Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference
9. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
10. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
11. WWMR Announces Pain Clinic Physicians Most Appreciated Companies: Pfizer, Eli Lilly and Endo Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)...  Pharmacyclics, Inc. (NASDAQ: PCYC ) ... newly developed Bruton,s tyrosine kinase (BTK) inhibitor for ... results of these preclinical evaluations have been communicated ... feedback received from the Agency is supportive of ... preclinical work is required to begin a Phase ...
(Date:2/27/2015)... The fully automated supercritical fluidic chromatography-based ... analyze up to 48 samples utilizing automatic extraction ... targets by mass spectrometry. , The Nexera ... requirements of a wide range of applications, including ... search for disease biomarkers, additives in forming polymers, ...
(Date:2/27/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... patients and health care advocates in the United States ... Rare Disease Day is dedicated to elevating public ... special challenges faced by patients with rare diseases and ... to stand alongside patients and caregivers representing the rare ...
(Date:2/26/2015)... WOODBRIDGE, N.J. , Feb. 26, 2015 ... and its affiliated companies, Wilentz, Goldman & ... a trade secrets lawsuit against Genewiz Inc. in excess ... obtained and utilized GenScript,s trade secrets, and that it ... court entered an order denying motions for judgment notwithstanding ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... KENILWORTH, N.J., Oct. 11 Schering-Plough,Corporation (NYSE: ... approval from,the European Commission for its planned acquisition ... announced March 12. Organon BioSciences is comprised ... the animal health business. It also,includes Nobilon, the ...
... Calif., Oct. 11 AMDL, Inc. (Amex:,ADL), ... Shenzhen,Jiangxi and Jilin, China, through its wholly ... international biopharma company that,engages in the development, ... products. AMDL announced today that JPI has,signed ...
... vascular tissue processing revenues in the third, quarter of 2007 increased ... ... ATLANTA, Oct. 11 CryoLife, Inc. (NYSE: CRY ),a ... preservation services revenues for the third quarter,of 2007 were approximately $21.9 ...
Cached Biology Technology:Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V. 2AMDL Expands Drug Distribution in China With Additional Agreement, Valued at $2.3 Million Annually 2CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 2CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 3CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 4CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 5
(Date:1/22/2015)... 13, 2015 Technology Showcase, Hall E -   EyeLock ... today announced it will showcase its EyeLock ID technology integrated ... Department of Energy,s Oak Ridge National Laboratory (ORNL) ... EyeLock,s iris identity authentication technology is being used to validate ...
(Date:1/22/2015)... Washington , January 20, 2015 Investorideas.com, ... tech stocks, releases video from the CES 2015 (Consumer Electronics ... Apollo Robbins . Apollo shows how easily ... smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... NEW YORK , Jan. 22, 2015   EyeLock, Inc. ... announced it has appointed Steve Gerber to the ... Gerber will be responsible for leading development of mobile platforms ... 25 years of success and innovation in the semiconductor industry ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... hosts a panel discussion and open public forum about ... for Biosecurity (NSABB), which advises the U.S. Department of ... journals that they redact key information from unpublished manuscripts ... both good and bad purposes. The research in ...
... 10, 2012  Trovagene, Inc. (Pink Sheets: TROV.PK), a ... Stephen Zaniboni has been named Chief Financial Officer. ... more than $500 million through venture financing and ... of healthcare software solutions company Awarepoint and XIFIN ...
... today that it will receive a tuberculosis (TB) biomarkers ... Challenges in Global Health program, an initiative that seeks ... can radically improve health in the developing world. Urs ... SomaLogic, will pursue an innovative research project to identify ...
Cached Biology News:Georgetown hosts forum to discuss government request of journals to redact scientific data 2Stephen Zaniboni Joins Trovagene, Inc. as Chief Financial Officer 2Stephen Zaniboni Joins Trovagene, Inc. as Chief Financial Officer 3SomaLogic Inc. receives Grand Challenges tuberculosis biomarkers grant 2
Rabbit polyclonal to MAL ( Abpromise for all tested applications). entrezGeneID: 4118 SwissProtID: P21145...
Anti-ADAM-12 (Meltrin Alpha); amino terminal region; rabbit host...
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Biology Products: